German discount reveal has drugmakers worried; Novo Nordisk teams up with NHS on diabetes; Shire looks to expand Elvanse;

> Germany's proposal to reveal drug discounts has Big Pharma worried that other countries will press for similarly low prices. Report

> Novo Nordisk ($NVO) teamed up with National Health Service primary care trusts on a diabetes-care program. Report

> Shire ($SHPG) filed its ADHD drug Elvanse for approval in the U.K., Denmark and Sweden; it's sold as Vyvanse in the U.S. Release

> Drug companies are increasing their use of key account managers to deal with payers and formulary decision-makers, but sales reps are still a necessary part of pharma marketing strategies. Report

> Ranbaxy Laboratories and Teva Pharmaceutical Industries ($TEVA) agreed to settle collusion claims with the New York Attorney General, in a probe of their generic Lipitor sales tactics. Report

And Finally... Apple ($AAPL) is looking to take a bite of the medical devices market. Report

Suggested Articles

UnitedHealthcare will stop covering Descovy in PrEP in favor of Truvada, which is on track to see low-cost generic competition in September.

FDA handed NS Pharma’s Viltepso a speedy FDA nod based on the same dystrophin production data that supported two Sarepta drugs' approvals.

Rapper, actress and producer Queen Latifah—whose mother died of sclerosis-associated lung disease—joined Boehringer's "More than Scleroderma” push.